Symbicort® Turbohaler; 200 micrograms/6 micrograms/inhalation, inhalation powder

Country: Ireland

Language: English

Source: HPRA (Health Products Regulatory Authority)

Active ingredient:

Budesonide; Formoterol fumatrate dihydrate

Available from:

AstraZeneca AB

ATC code:

R03AK

INN (International Name):

Budesonide; Formoterol fumatrate dihydrate

Dosage:

200 mcg/6 microgram(s)

Pharmaceutical form:

Inhalation powder

Prescription type:

Product subject to prescription which may be renewed (B)

Therapeutic area:

Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics

Authorization status:

Marketed

Authorization date:

2001-02-23

Patient Information leaflet

PACKAGE LEAFLET: INFORMATION FOR THE USER
SYMBICORT
® TURBOHALER
® 200 MICROGRAMS/6 MICROGRAMS/INHALATION, INHALATION POWDER
Budesonide/Formoterol fumarate dihydrate
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.

Keep this leaflet. You may need to read it again.

If you have any further questions, ask your doctor or pharmacist.

This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.

If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET:
1.
What Symbicort Turbohaler is and what it is used for
2.
What you need to know before you use Symbicort Turbohaler
3.
How to use Symbicort Turbohaler
4.
Possible side effects
5.
How to store Symbicort Turbohaler
6.
Contents of the pack and other information
1. WHAT SYMBICORT TURBOHALER IS AND WHAT IT IS USED FOR
Symbicort Turbohaler is an inhaler that is used to treat asthma in
adults and adolescents aged 12 to
17 years. It is also used to treat the symptoms of Chronic Obstructive
Pulmonary Disease (COPD) in
adults aged 18 years and older. It contains two different medicines:
budesonide and formoterol
fumarate dihydrate.

Budesonide belongs to a group of medicines called
‘corticosteroids’. It works by reducing and
preventing swelling and inflammation in your lungs.

Formoterol fumarate dihydrate belongs to a group of medicines called
‘long-acting beta
2
adrenoceptor agonists’ or ‘bronchodilators’. It works by
relaxing the muscles in your airways.
This helps you to breathe more easily.
ASTHMA
Symbicort Turbohaler can be prescribed for asthma in two different
ways.
A) SOME PEOPLE ARE PRESCRIBED TWO ASTHMA INHALERS:
SYMBICORT TURBOHALER AND A SEPARATE
‘RELIEVER INHALER’.

They use Symbicort Turbohaler every day. This helps to prevent asthma
symptoms from
happe

Summary of Product characteristics

Health Products Regulatory Authority
03 March 2021
CRN009ZTG
Page 1 of 11
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Symbicort® Turbohaler; 200 micrograms/6 micrograms/inhalation,
inhalation powder
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each delivered dose (the dose that leaves the mouthpiece) contains:
budesonide 160 micrograms/inhalation and formoterol
fumarate dihydrate 4.5 micrograms/inhalation.
Each metered dose contains: budesonide 200 micrograms/inhalation and
formoterol fumarate dihydrate
6 micrograms/inhalation.
Excipient with known effect
Lactose monohydrate 730 micrograms per delivered dose.
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Inhalation powder.
White powder.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
ASTHMA
Symbicort Turbohaler is indicated in adults and adolescents (12 years
and older) for the regular treatment of asthma where use
of a combination (inhaled corticosteroid and long-acting β
2
adrenoceptor agonist) is appropriate:

patients not adequately controlled with inhaled corticosteroids and
“as needed” inhaled short-acting β
2
adrenoceptor agonists.
or

patients already adequately controlled on both inhaled corticosteroids
and long-acting β
2
adrenoceptor agonists.
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Symbicort Turbohaler is indicated in adults, aged 18 years and older,
for the symptomatic treatment of patients with COPD
with forced expiratory volume in 1 second (FEV
1
) <70% predicted normal (post-bronchodilator) and an exacerbation
history
despite regular bronchodilator therapy (see also section 4.4).
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Route of administration: For inhalation use.
Posology
ASTHMA
Symbicort Turbohaler is not intended for the initial management of
asthma. The dosage of the components of Symbicort is
individual and should be adjusted to the severity of the disease. This
should be considered not only when treatment with
combination products is initiated but also when the maintenance